Early trial tests new drug combo for kids with tough cancers
NCT ID NCT04544995
Summary
This early-stage study aimed to find a safe and effective dose of a two-drug combination (niraparib and dostarlimab) for children and adolescents whose solid tumors returned or did not respond to standard treatments. It involved 47 young participants with cancers like osteosarcoma and neuroblastoma. The main goals were to determine the safest dose for future studies and to see if the treatment could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Birmingham, B4 6NH, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.